Articles related to IMMUNOTHERAPY

In cisplatin-eligible patients with muscle-invasive bladder cancer, perioperative durvalumab combined with standard chemotherapy demonstrated an 8% absolute improvement in event-free survival at 24 months compared to chemotherapy alone.

A recent phase 3 trial comparing nivolumab plus AVD to brentuximab vedotin plus AVD in advanced-stage Hodgkin’s lymphoma demonstrated a significant improvement in 2-year progression-free survival (92% vs. 83%, respectively) with a hazard ratio for disease progression or death of 0.45 (95% CI, 0.30 to 0.65).

The study’s findings highlight the complex interplay between CAR T cell therapy and cytokine signaling in AML treatment, suggesting new avenues for improving outcomes in this challenging disease.

Chemotherapy-free regimens for Ph+ ALL have shown complete response rates of 94-100% with minimal toxicity, potentially eliminating the need for stem cell transplant in many patients.

The STRIDE regimen demonstrated a 30.7% survival rate at 36 months, compared to 20.2% with sorafenib, suggesting potential long-term benefits for patients with unresectable hepatocellular carcinoma.

Adjuvant durvalumab therapy led to a median overall survival of 55.9 months compared to 33.4 months with placebo in patients with limited-stage small-cell lung cancer who did not progress after chemoradiotherapy.